PURPOSE: Clinical trials and guidelines published between 1997 and 2001 concluded that postmastectomy radiotherapy (PMRT) improves overall survival for women with high-risk breast cancer. However, the effect of these findings on current practice is not known. Using the Surveillance, Epidemiology, and End Results-Medicare cohort, we sought to characterize the adoption of PMRT from 1992 to 2002 and identify risk factors for PMRT omission among high-risk older patients. METHODS AND MATERIALS: We identified 28,973 women aged > or =66 years who had been treated with mastectomy for invasive breast cancer between 1992 and 2002. Trends in the adoption of PMRT for low- (T1-T2N0), intermediate- (T1-T2N1), and high- (T3-T4 and/or N2-N3) risk patients were characterized using a Monte Carlo permutation algorithm. Multivariate logistic regression identified the risk factors for PMRT omission and calculated the adjusted use rates. RESULTS: Postmastectomy radiotherapy use increased gradually and consistently for low-risk (+2.16%/y) and intermediate-risk (+7.20%/y) patients throughout the study interval. In contrast, PMRT use for high-risk patients increased sharply between 1996 and 1997 (+30.99%/y), but subsequently stabilized. Between 1998 and 2002, only 53% of high-risk patients received PMRT. The risk factors for PMRT omission included advanced age, moderate to severe comorbidity, smaller tumor size, fewer positive lymph nodes, and geographic region, with adjusted use rates ranging from 63.5% in San Francisco to 44.9% in Connecticut. CONCLUSION: Among the high-risk patients, PMRT use increased sharply in 1997 after the initial clinical trial publication. Despite subsequent guidelines recommending the use of PMRT, no further increase in PMRT use has occurred, and nearly 50% of high-risk patients still do not receive PMRT.
PURPOSE: Clinical trials and guidelines published between 1997 and 2001 concluded that postmastectomy radiotherapy (PMRT) improves overall survival for women with high-risk breast cancer. However, the effect of these findings on current practice is not known. Using the Surveillance, Epidemiology, and End Results-Medicare cohort, we sought to characterize the adoption of PMRT from 1992 to 2002 and identify risk factors for PMRT omission among high-risk older patients. METHODS AND MATERIALS: We identified 28,973 women aged > or =66 years who had been treated with mastectomy for invasive breast cancer between 1992 and 2002. Trends in the adoption of PMRT for low- (T1-T2N0), intermediate- (T1-T2N1), and high- (T3-T4 and/or N2-N3) risk patients were characterized using a Monte Carlo permutation algorithm. Multivariate logistic regression identified the risk factors for PMRT omission and calculated the adjusted use rates. RESULTS: Postmastectomy radiotherapy use increased gradually and consistently for low-risk (+2.16%/y) and intermediate-risk (+7.20%/y) patients throughout the study interval. In contrast, PMRT use for high-risk patients increased sharply between 1996 and 1997 (+30.99%/y), but subsequently stabilized. Between 1998 and 2002, only 53% of high-risk patients received PMRT. The risk factors for PMRT omission included advanced age, moderate to severe comorbidity, smaller tumor size, fewer positive lymph nodes, and geographic region, with adjusted use rates ranging from 63.5% in San Francisco to 44.9% in Connecticut. CONCLUSION: Among the high-risk patients, PMRT use increased sharply in 1997 after the initial clinical trial publication. Despite subsequent guidelines recommending the use of PMRT, no further increase in PMRT use has occurred, and nearly 50% of high-risk patients still do not receive PMRT.
Authors: Reshma Jagsi; Paul Abrahamse; Monica Morrow; Sarah T Hawley; Jennifer J Griggs; John J Graff; Ann S Hamilton; Steven J Katz Journal: J Clin Oncol Date: 2010-03-29 Impact factor: 44.544
Authors: Shervin M Shirvani; Ritsuko Komaki; John V Heymach; Frank V Fossella; Joe Y Chang Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-12 Impact factor: 7.038
Authors: Michael T Vest; Lynn Tanoue; Pamela R Soulos; Anthony W Kim; Frank Detterbeck; Daniel Morgensztern; Cary P Gross Journal: J Thorac Oncol Date: 2012-01 Impact factor: 15.609
Authors: Grace L Smith; Ya-Chen T Shih; Ying Xu; Sharon H Giordano; Benjamin D Smith; George H Perkins; Welela Tereffe; Wendy A Woodward; Thomas A Buchholz Journal: Cancer Date: 2010-02-01 Impact factor: 6.860
Authors: Frederik Wenz; Elena Sperk; Wilfried Budach; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Marc D Piroth; Marie-Luise Sautter-Bihl; Felix Sedlmayer; Rainer Souchon; Christoph Fussl; Rolf Sauer Journal: Strahlenther Onkol Date: 2014-08 Impact factor: 3.621
Authors: Michael T Vest; Jeph Herrin; Pamela R Soulos; Roy H Decker; Lynn Tanoue; Gaetane Michaud; Anthony W Kim; Frank Detterbeck; Daniel Morgensztern; Cary P Gross Journal: Chest Date: 2013-02-01 Impact factor: 9.410
Authors: Jean B Owen; Najma Khalid; Alex Ho; Lisa A Kachnic; Ritsuko Komaki; May Lin Tao; Adam Currey; J Frank Wilson Journal: J Oncol Pract Date: 2014-03-18 Impact factor: 3.840